Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Ductal carcinoma in situ (DCIS), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Distinguishing DCIS that would progress from DCIS that would not; molecular classifiers, mammographic AI and the monitoring trials are the route.
Long-term safety of active monitoring beyond two years; LORIS and LORD follow-up and the COMET ten-year endpoint will tell.
Overtreatment by mastectomy remains common; shared decision aids and radiotherapy omission tools are the response.
Preventing progression pharmacologically or with vaccines (HER2-directed DCIS vaccine trials) rather than surgically.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Active monitoring with mammography every six months and optional endocrine therapy, in trials (COMET, LORIS, LORD) or after shared decision-making where guidelines allow.
At two years the rate of ipsilateral invasive cancer with active monitoring was non-inferior to guideline-concordant surgery.
Hwang and colleagues (JAMA, December 2024); first randomised evidence for monitoring low-risk DCIS.
10-year ipsilateral breast tumour recurrence 4.
Tamoxifen 5 mg daily for three years roughly halved breast cancer events compared with placebo with few serious adverse effects.